Vitaxin

Vitaxin (MEDI-523): An Angiogenesis Inhibitor[edit | edit source]

Vitaxin (MEDI-523) is a humanized monoclonal antibody designed to target the vascular integrin alpha-v beta-3, playing a significant role in angiogenesis inhibition. With implications for the treatment of various cancers, Vitaxin's development and clinical investigation have underscored its potential therapeutic utility, as well as its safety profile.

Background[edit | edit source]

Classification: Humanized monoclonal antibody.
Target: Vascular integrin alpha-v beta-3.

Mechanism of Action[edit | edit source]

Vitaxin functions as an antagonist to the vascular integrin alpha-v beta-3. This integrin is central to the process of angiogenesis, or the formation of new blood vessels, which is a crucial process for the growth and survival of tumors^[1].

Therapeutic Applications[edit | edit source]

Cancer Treatment: Due to its inhibitory effects on angiogenesis, Vitaxin has been investigated as a therapeutic agent in the management of several cancers. The ability to curtail blood vessel formation can deprive tumors of necessary nutrients, leading to their stagnation or regression.
Rheumatoid Arthritis: In 2002, researchers began exploring the potential of Vitaxin in treating rheumatoid arthritis, a chronic inflammatory condition that can benefit from angiogenesis inhibition^[2].

Developmental Lineage[edit | edit source]

Origin: Vitaxin is derived from the mouse antibody LM609.
Successor: Vitaxin served as the developmental precursor for Etaracizumab (MEDI-522), which also targets the same integrin.

Clinical Assessment[edit | edit source]

Safety Profile: Clinical studies have demonstrated that Vitaxin is well-tolerated and safe for human administration^[3].
Efficacy: While safe, its therapeutic efficacy for advanced cancers appears to be limited. Further studies are necessary to determine the best applications and patient populations for Vitaxin treatment^[4].

Conclusion[edit | edit source]

Vitaxin, as an angiogenesis inhibitor, embodies the potential of targeted therapies in the realm of oncology and other diseases. Its safety profile encourages further investigation into its therapeutic applications, while its developmental lineage has spurred the creation of subsequent compounds, broadening the scope of this class of drugs.

Vitaxin Resources
Latest articles Most recent articles Ongoing trials	Wikipedia

↑ Brooks PC, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79(7):1157-1164.
↑ Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med. 2003;9(10):1245-1250.
↑ Dechantsreiter MA, et al. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem. 1999;42(16):3033-3040.
↑ Gutheil JC, et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res. 2000;6(8):3056-3061.

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Translate this page: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

[1] Brooks PC, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79(7):1157-1164.

[2] Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med. 2003;9(10):1245-1250.

[3] Dechantsreiter MA, et al. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem. 1999;42(16):3033-3040.

[4] Gutheil JC, et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res. 2000;6(8):3056-3061.

[1]

[2]

[3]

[4]